Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

[1]  O. Doumbo,et al.  Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali , 2017, Malaria Journal.

[2]  Dhruviben S. Patel,et al.  Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015 , 2017, Malaria Journal.

[3]  D. Kwiatkowski,et al.  Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. , 2017, The Lancet. Infectious diseases.

[4]  N. White,et al.  Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam , 2017, Malaria Journal.

[5]  D. Ménard,et al.  Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia. , 2016, The American journal of tropical medicine and hygiene.

[6]  S. Abdulla,et al.  Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms , 2016, PloS one.

[7]  Saorin Kim,et al.  Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia , 2016, Antimicrobial Agents and Chemotherapy.

[8]  I. Hastings,et al.  Measuring windows of selection for anti-malarial drug treatments , 2015, Malaria Journal.

[9]  N. Lucchi,et al.  Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola , 2014, Antimicrobial Agents and Chemotherapy.

[10]  E. Purssell,et al.  Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? , 2014, Malaria research and treatment.

[11]  S. Nair,et al.  Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria , 2014, The Cochrane database of systematic reviews.

[12]  S. Donegan,et al.  Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria , 2014, The Cochrane database of systematic reviews.

[13]  S. Duparc,et al.  Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials , 2013, Malaria Journal.

[14]  Cho Naing,et al.  Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. , 2013, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  O. Doumbo,et al.  Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial , 2012, Malaria Journal.

[16]  J. Gaudart,et al.  Repeated Artemisinin-Based Combination Therapies in a Malaria Hyperendemic Area of Mali: Efficacy, Safety, and Public Health Impact , 2012, The American journal of tropical medicine and hygiene.

[17]  S. Abdulla,et al.  Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. , 2012, The New England journal of medicine.

[18]  Guosheng Yin,et al.  Fundamentals of Clinical Trials , 2012 .

[19]  J. Beeson.  A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial , 2011, PLoS medicine.

[20]  B. Cissé,et al.  Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial , 2011, Malaria Journal.

[21]  M. Petzold,et al.  Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  E. Tjitra,et al.  Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial , 2011, PloS one.

[23]  Elizabeth Ashley,et al.  Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.

[24]  A. Dicko,et al.  Évaluation de l’effet de différentes combinaisons thérapeutiques à base d’artémisinine, sur l’incidence du paludisme dans une zone hyperendémique de paludisme au Mali , 2010 .

[25]  P. Newton,et al.  An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia , 2010, PloS one.

[26]  O. Gaye,et al.  Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial , 2010, The Lancet.

[27]  Q. Bassat,et al.  Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial , 2009, PloS one.

[28]  O. Rodrigues,et al.  Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up , 2008, Malaria Journal.

[29]  A. Gautam,et al.  Safety, Tolerability, and Single‐ and Multiple‐Dose Pharmacokinetics of Piperaquine Phosphate in Healthy Subjects , 2008, Journal of clinical pharmacology.

[30]  P. Rosenthal,et al.  Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  U. d’Alessandro,et al.  A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru , 2007, PloS one.

[32]  R. Price,et al.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.

[33]  K. Stepniewska,et al.  Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison , 2006, The Lancet.

[34]  A. Rosanas-Urgell,et al.  Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Global health.

[35]  A. Dicko,et al.  Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. , 2016, The Lancet. Infectious diseases.

[36]  C. Karema,et al.  A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial , 2011 .

[37]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[38]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .